How DDA Is Strengthening CMC Support Across the R&D Continuum

As drug development programs advance, the challenges they face evolve, but the cost of misalignment remains constant. Gaps in CMC can quietly derail timelines, strain resources, and introduce unnecessary risk at critical inflection points.

Recognizing this reality, Drug Discovery Alliances (DDA) is expanding its CMC consulting network to provide deeper, more flexible support across every phase of R&D, from discovery through commercial launch.

CMC Expertise When and Where It’s Needed Most

CMC demands rarely arrive neatly packaged. Early discovery teams may need strategic guidance, while later stage programs require hands on execution to meet regulatory and manufacturing milestones. DDA’s expanded CMC offering is designed to meet clients exactly where they are.

Through this initiative, clients gain access to seasoned CMC consultants with decades of experience navigating complex development pathways. Engagements can be structured around specific deliverables or through ongoing flex FTE support, allowing teams to scale expertise based on urgency, program stage, and internal capacity.

This flexibility ensures progress without overbuilding internal infrastructure too early.

Proof in Motion: Supporting Active Biotech Programs

DDA is currently supporting multiple biotech companies through this expanded CMC initiative, providing not just advisory insight, but execution focused leadership. These consultants bring deep technical expertise paired with practical, real world experience, helping teams move from strategy to action.

Rather than operating in isolation, DDA’s model emphasizes alignment, connecting CMC activities with regulatory expectations, supply chain realities, and long term development goals.

Where DDA Helps

The expanded CMC consulting network supports a wide range of development needs, including:

• API and supply chain management

• Quality assurance

• Analytical development

• Regulatory strategy

• Formulation

• Drug product development

By integrating these capabilities, DDA helps ensure that decisions made today do not become constraints tomorrow.

Interim and Fractional Leadership to Drive Early Execution

In addition to technical consulting, DDA now offers interim and fractional C suite support, providing experienced leadership at moments when execution speed matters most. These executives help translate development strategy into actionable plans, aligning vendors, timelines, and resources to reach IND and key manufacturing readiness milestones.

For startups and emerging biotech companies, this leadership can be transformative, bringing structure, clarity, and momentum during critical growth phases.

A Connected Approach to Development

At its core, DDA’s expanded CMC offering reflects a broader philosophy. Drug development succeeds when expertise is connected, not siloed. By bridging discovery, development, and manufacturing with trusted alliance partners, DDA helps clients reduce risk, maintain momentum, and focus on advancing high quality programs toward the clinic and beyond.

As development complexity continues to grow, so does the need for experienced guidance and seamless execution. With its expanded CMC consulting network, DDA is strengthening its ability to support that journey every step of the way.